1 month Phathom Pharmaceuticals (PHAT) Upgraded to Buy: Here’s What You Should Know Zacks
Phathom Pharmaceuticals (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
X